[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,713,239
  • Shares Outstanding, K 124,433
  • Annual Sales, $ 88,040 K
  • Annual Income, $ -784,960 K
  • EBIT $ -640 M
  • EBITDA $ -630 M
  • 60-Month Beta 0.38
  • Price/Sales 111.33
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 41.05% (-0.74%)
  • Historical Volatility 59.93%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 183.58% on 05/04/26
  • IV Low 41.05% on 05/22/26
  • Expected Move (DTE 27) 6.08 (7.91%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 2,098
  • Volume Avg (30-Day) 8,881
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 95,749
  • Open Int (30-Day) 125,881
  • Expected Range 70.74 to 82.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.63
  • Number of Estimates 9
  • High Estimate $-1.53
  • Low Estimate $-1.73
  • Prior Year $-1.12
  • Growth Rate Est. (year over year) -45.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.65 +30.89%
on 04/29/26
80.20 -4.29%
on 05/05/26
+10.51 (+15.86%)
since 04/22/26
3-Month
58.43 +31.37%
on 03/13/26
80.20 -4.29%
on 05/05/26
+8.82 (+12.98%)
since 02/20/26
52-Week
29.81 +157.50%
on 05/27/25
80.20 -4.29%
on 05/05/26
+46.28 (+151.80%)
since 05/22/25

Most Recent Stories

More News
Cytokinetics to Hold Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026...

CYTK : 76.84 (-1.56%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2026 it granted stock options to purchase an aggregate of 20,807...

CYTK : 76.84 (-1.56%)
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

Third Annual Muscle Biology-Focused Research Symposium  Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:...

CYTK : 76.84 (-1.56%)
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in a fireside chat...

CYTK : 76.84 (-1.56%)
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety   SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)...

CYTK : 76.84 (-1.56%)
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of an underwritten public offering of 11,338,028 shares of its common...

CYTK : 76.84 (-1.56%)
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common...

CYTK : 76.84 (-1.56%)
Cytokinetics: Q1 Earnings Snapshot

Cytokinetics: Q1 Earnings Snapshot

CYTK : 76.84 (-1.56%)
Cytokinetics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million...

CYTK : 76.84 (-1.56%)
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ...

CYTK : 76.84 (-1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 80.39
2nd Resistance Point 79.74
1st Resistance Point 78.90
Last Price 76.84
1st Support Level 77.41
2nd Support Level 76.76
3rd Support Level 75.92

See More

52-Week High 80.20
Last Price 76.84
Fibonacci 61.8% 60.95
Fibonacci 50% 55.00
Fibonacci 38.2% 49.06
52-Week Low 29.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.